"VSports注册入口" Immune Checkpoint Therapy in Renal Cell Carcinoma
- PMID: 27111903
- DOI: 10.1097/PPO.0000000000000177
Immune Checkpoint Therapy in Renal Cell Carcinoma
Abstract
Renal cell carcinoma (RCC) is a largely chemotherapy-resistant disease that is commonly treated with molecularly targeted therapies. Evidence suggests that RCC is also an immune-responsive disease, and checkpoint inhibitors are in active development as agents for the treatment of systemic disease. Programmed cell death 1 (PD-1) is an inhibitory immune checkpoint, and blockade of the PD-1 cascade is an attractive target in RCC. Expression of the ligand for PD-1 in RCC has been shown to be a negative prognostic factor; however, response to PD-1 blockade is not restricted to tumors expressing the ligand for PD-1. Nivolumab is the most completely characterized anti-PD-1 agent in RCC and has been shown to be efficacious as monotherapy VSports手机版. Currently, there are multiple ongoing clinical trials exploring the use of combination therapy with PD-1 blockade. .
Publication types
- "VSports手机版" Actions
MeSH terms
- "VSports注册入口" Actions
- "V体育安卓版" Actions
- VSports最新版本 - Actions
- V体育官网入口 - Actions
- Actions (VSports)
- Actions (V体育官网)
- V体育官网入口 - Actions
- "VSports在线直播" Actions
- "V体育官网入口" Actions
- V体育安卓版 - Actions
Substances
- V体育平台登录 - Actions
LinkOut - more resources
Full Text Sources (V体育官网)
Other Literature Sources (VSports在线直播)
Medical
